These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 26999507)

  • 1. Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody.
    Wang C; Ye Y; Hochu GM; Sadeghifar H; Gu Z
    Nano Lett; 2016 Apr; 16(4):2334-40. PubMed ID: 26999507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photothermal therapy mediated by phase-transformation nanoparticles facilitates delivery of anti-PD1 antibody and synergizes with antitumor immunotherapy for melanoma.
    Zhang N; Song J; Liu Y; Liu M; Zhang L; Sheng D; Deng L; Yi H; Wu M; Zheng Y; Wang Z; Yang Z
    J Control Release; 2019 Jul; 306():15-28. PubMed ID: 31132380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors.
    Ye Y; Wang J; Hu Q; Hochu GM; Xin H; Wang C; Gu Z
    ACS Nano; 2016 Sep; 10(9):8956-63. PubMed ID: 27599066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
    Han X; Li H; Zhou D; Chen Z; Gu Z
    Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Dual-Bioresponsive Drug-Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade.
    Ruan H; Hu Q; Wen D; Chen Q; Chen G; Lu Y; Wang J; Cheng H; Lu W; Gu Z
    Adv Mater; 2019 Apr; 31(17):e1806957. PubMed ID: 30856290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug.
    Shen N; Yang C; Zhang X; Tang Z; Chen X
    Acta Biomater; 2021 Nov; 135():543-555. PubMed ID: 34400305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of microneedle-assisted co-delivery platform and its combining photodynamic/immunotherapy.
    Chen SX; Ma M; Xue F; Shen S; Chen Q; Kuang Y; Liang K; Wang X; Chen H
    J Control Release; 2020 Aug; 324():218-227. PubMed ID: 32387551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-delivery of dendritic cell vaccine and anti-PD-1 antibody with cryomicroneedles for combinational immunotherapy.
    Chang H; Wen X; Li Z; Ling Z; Zheng Y; Xu C
    Bioeng Transl Med; 2023 Sep; 8(5):e10457. PubMed ID: 37693072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracorneal injection of a detachable hybrid microneedle for sustained drug delivery.
    Lee K; Song HB; Cho W; Kim JH; Kim JH; Ryu W
    Acta Biomater; 2018 Oct; 80():48-57. PubMed ID: 30267886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth.
    Doleschel D; Hoff S; Koletnik S; Rix A; Zopf D; Kiessling F; Lederle W
    J Exp Clin Cancer Res; 2021 Sep; 40(1):288. PubMed ID: 34517894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Built-In Active Microneedle Patch with Enhanced Autonomous Drug Delivery.
    Lopez-Ramirez MA; Soto F; Wang C; Rueda R; Shukla S; Silva-Lopez C; Kupor D; McBride DA; Pokorski JK; Nourhani A; Steinmetz NF; Shah NJ; Wang J
    Adv Mater; 2020 Jan; 32(1):e1905740. PubMed ID: 31682039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioresponsive Protein Complex of aPD1 and aCD47 Antibodies for Enhanced Immunotherapy.
    Chen Q; Chen G; Chen J; Shen J; Zhang X; Wang J; Chan A; Gu Z
    Nano Lett; 2019 Aug; 19(8):4879-4889. PubMed ID: 31294571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.
    van Hooren L; Sandin LC; Moskalev I; Ellmark P; Dimberg A; Black P; Tötterman TH; Mangsbo SM
    Eur J Immunol; 2017 Feb; 47(2):385-393. PubMed ID: 27873300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissolvable Self-Locking Microneedle Patches Integrated with Immunomodulators for Cancer Immunotherapy.
    Joo SH; Kim J; Hong J; Fakhraei Lahiji S; Kim YH
    Adv Mater; 2023 Mar; 35(10):e2209966. PubMed ID: 36528846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of a core-shell microneedle system to achieve targeted co-delivery of checkpoint inhibitors for melanoma immunotherapy.
    Yang P; Lu C; Qin W; Chen M; Quan G; Liu H; Wang L; Bai X; Pan X; Wu C
    Acta Biomater; 2020 Mar; 104():147-157. PubMed ID: 31904558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing Deep-Seated Melanoma Therapy through Wearable Self-Powered Microneedle Patch.
    Wang C; He G; Zhao H; Lu Y; Jiang P; Li W
    Adv Mater; 2024 Mar; 36(11):e2311246. PubMed ID: 38123765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smart vaccine delivery based on microneedle arrays decorated with ultra-pH-responsive copolymers for cancer immunotherapy.
    Duong HTT; Yin Y; Thambi T; Nguyen TL; Giang Phan VH; Lee MS; Lee JE; Kim J; Jeong JH; Lee DS
    Biomaterials; 2018 Dec; 185():13-24. PubMed ID: 30216806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
    Komatsubara KM; Carvajal RD
    Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of immunotherapy for metastatic mucosal melanoma.
    Shreders A; Joseph RW
    Immunotherapy; 2016 Jul; 8(8):843-5. PubMed ID: 27381682
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.